Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

2015120 citationsJournal Articlebronze Open Access

Authors

Shiv K. Gupta · Mayo Clinic

Sani H. Kizilbash · Mayo Clinic

Brett L. Carlson · Mayo Clinic

Ann C. Mladek · Mayo Clinic

Felix Boakye‐Agyeman · Mayo Clinic

Katrina K. Bakken · Mayo Clinic

Jenny L. Pokorny · Mayo Clinic

Abstract

Veliparib statistically significantly enhances (P < .001) the efficacy of TMZ in tumors with MGMT promoter hypermethylation. Based on these data, MGMT promoter hypermethylation is being used as an eligibility criterion for A071102 (NCT02152982), the phase II/III clinical trial evaluating TMZ/veliparib combination in patients with GBM.

Topics & Keywords

Glioma Diagnosis and Treatment PARP inhibition in cancer therapy Brain Metastases and Treatment

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 108, Issue 5, pp. djv369-djv369

DOI: 10.1093/jnci/djv369

Field-Weighted Citation Impact: 4.67

Command Palette

Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Authors

Abstract

Topics & Keywords

Publication Details